Potential conflicts of interest. S. N. reports grants from Gilead Sciences and ViiV Healthcare and consulting fees and payment or honoraria for educational engagements from Gilead Sciences, Janssen-Cilag, MSD, and ViiV Healthcare. A. R. G. reports consulting fees from Mylan and Janssen; payment or honoraria for educational engagements from Gilead Sciences and ViiV Healthcare; payment for expert testimony from Janssen; and travel support from Gilead Sciences, ViiV Healthcare, and MSD. G. R. reports consulting fees from Gilead Sciences, ViiV Healthcare, Janssen, BMS, and MSD; payment or honoraria for educational engagements from Gilead Sciences and ViiV Healthcare; and travel support from Gilead Sciences, ViiV Healthcare, and MSD. S. A. reports grants or contracts and payment or honoraria for educational engagements from Pfizer. A. G. reports grants or contracts from ViiV Healthcare, Bristol-Myers Squibb, and Gilead Sciences and consulting fees, travel support, and payment or honoraria for educational engagements from ViiV Healthcare, Gilead Sciences, Janssen-Cilag, Merck Sharp & Dohme, Bristol-Myers Squibb, Pfizer, and Novartis. M. V. C. reports payment or honoraria for educational engagements from Gilead Sciences and travel support from Gilead Sciences and ViiV Healthcare. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.